	US 12,462,905 B2
	Systems and methods for dispensing a statin medication over the counter
James Blasetto, Chadds Ford, PA (US); Judy Firor, Landenberg, PA (US); David Guiga, West Chester, PA (US); William Mongan, Malvern, PA (US); Robert Prybolsky, West Chester, PA (US); and Richard L. Skelly, Flourtown, PA (US)
Assigned to ASTRAZENECA UK LIMITED, Cambridge (GB)
Filed by AstraZeneca UK Limited, Cambridge (GB)
Filed on Mar. 26, 2024, as Appl. No. 18/617,468.
Application 18/617,468 is a continuation of application No. 17/323,138, filed on May 18, 2021, granted, now 11,972,844.
Application 17/323,138 is a continuation of application No. 16/791,745, filed on Feb. 14, 2020, granted, now 11,031,104, issued on Jun. 8, 2021.
Application 16/791,745 is a continuation of application No. 15/385,747, filed on Dec. 20, 2016, granted, now 10,600,502, issued on Mar. 24, 2020.
Prior Publication US 2025/0061982 A1, Feb. 20, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 10/20 (2018.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 20/13 (2018.01); G16H 70/20 (2018.01); G06Q 50/22 (2024.01)

CPC G16H 10/20 (2018.01) [G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 20/13 (2018.01); G16H 70/20 (2018.01); G06Q 50/22 (2013.01)]

21 Claims

21. A method for requalifying a human subject for delivery of a statin pharmaceutical composition over-the-counter to lower cholesterol, comprising:

A) at a computer system comprising one or more processors and a memory, the memory comprising non-transitory instructions executed by the one or more processors that:

conduct a reorder survey thereby obtaining a plurality of reorder survey results from the subject, wherein the plurality of reorder survey results comprises:

whether the subject has experienced a muscle irregularity since taking the statin pharmaceutical composition,

when the subject is female, whether the subject is pregnant,

whether the subject is taking a medication that interacts with the statin pharmaceutical composition, and

whether the subject had an atherosclerotic cardiovascular event or a heart procedure since last ordering the statin pharmaceutical composition; and

apply a process to the first plurality of survey results, wherein the process comprises:

i) running all or a portion of the plurality of reorder survey results against a plurality of reorder filters, wherein, when a respective reorder filter in the plurality of reorder filters is fired, the process is terminated, or the subject is provided with a warning corresponding to the respective reorder filter, and wherein the plurality of reorder filters comprises:

a muscle irregularity filter,

a pregnancy filter,

a drug interaction filter, and

an atherosclerotic cardiovascular event filter;

ii) obtaining, when the process is not terminated, acknowledgment from the subject for each warning issued to the subject by any reorder filter in the plurality of reorder filters; and

iii) proceeding with the process when 1) the process is not already terminated by the firing of a reorder filter in the plurality of reorder filters and 2) the subject has acknowledged each warning associated with each reorder filter in the plurality of reorder filters that was fired and that is associated with a warning, wherein the process further comprises:

storing an indication in a subject profile of a reorder for the statin pharmaceutical composition,

communicating an over the counter drug facts label for the statin pharmaceutical composition to the subject, and

authorizing, upon confirmation from the subject that the over the counter drug facts label has been received and read, a provision of the statin pharmaceutical composition to the subject; and

B) administering the statin pharmaceutical composition to the subject after the authorizing, to lower cholesterol.